Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Recommendation of “Buy” from Analysts

Vera Therapeutics, Inc. (NASDAQ:VERAGet Free Report) has been assigned an average rating of “Buy” from the eight brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $26.29.

A number of research analysts recently commented on VERA shares. Wedbush increased their price target on shares of Vera Therapeutics from $16.00 to $21.00 and gave the company a “neutral” rating in a report on Friday, January 26th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Vera Therapeutics in a report on Wednesday, December 27th. Raymond James raised shares of Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $29.00 to $37.00 in a report on Friday, January 26th. Oppenheimer began coverage on shares of Vera Therapeutics in a report on Thursday, January 25th. They issued an “outperform” rating and a $26.00 price target for the company. Finally, Cantor Fitzgerald began coverage on shares of Vera Therapeutics in a research note on Monday, January 8th. They issued an “overweight” rating for the company.

Get Our Latest Report on Vera Therapeutics

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, Director Maha Katabi bought 161,290 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The stock was bought at an average cost of $31.00 per share, for a total transaction of $4,999,990.00. Following the completion of the transaction, the director now directly owns 3,628,446 shares of the company’s stock, valued at approximately $112,481,826. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Maha Katabi bought 161,290 shares of the stock in a transaction dated Tuesday, January 30th. The shares were acquired at an average cost of $31.00 per share, with a total value of $4,999,990.00. Following the purchase, the director now directly owns 3,628,446 shares in the company, valued at approximately $112,481,826. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Commodore Capital Lp sold 1,050,000 shares of the stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $18.00, for a total transaction of $18,900,000.00. Following the sale, the insider now directly owns 4,400,000 shares in the company, valued at $79,200,000. The disclosure for this sale can be found here. 22.60% of the stock is currently owned by insiders.

Institutional Trading of Vera Therapeutics

Hedge funds have recently bought and sold shares of the business. Innovis Asset Management LLC purchased a new position in shares of Vera Therapeutics during the 2nd quarter worth approximately $348,000. American International Group Inc. boosted its position in Vera Therapeutics by 55.4% in the 2nd quarter. American International Group Inc. now owns 16,275 shares of the company’s stock valued at $261,000 after buying an additional 5,799 shares during the period. Commodore Capital LP boosted its position in Vera Therapeutics by 93.0% in the 2nd quarter. Commodore Capital LP now owns 5,450,000 shares of the company’s stock valued at $87,472,000 after buying an additional 2,625,971 shares during the period. Principal Financial Group Inc. purchased a new position in Vera Therapeutics in the 2nd quarter valued at approximately $212,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Vera Therapeutics in the 3rd quarter valued at approximately $79,000. Institutional investors and hedge funds own 84.82% of the company’s stock.

Vera Therapeutics Price Performance

NASDAQ VERA opened at $44.89 on Tuesday. The stock has a market capitalization of $2.36 billion, a price-to-earnings ratio of -15.48 and a beta of 1.02. The business’s fifty day moving average price is $21.27 and its 200-day moving average price is $16.98. The company has a debt-to-equity ratio of 0.20, a current ratio of 6.97 and a quick ratio of 6.97. Vera Therapeutics has a 1-year low of $5.95 and a 1-year high of $46.59.

Vera Therapeutics Company Profile

(Get Free Report

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis.

See Also

Analyst Recommendations for Vera Therapeutics (NASDAQ:VERA)

Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.